Clinical-Prostate cancer A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy

Sun JiaLe; Zhang ZhiYu; OuYang Jun

首页> 外文期刊>Urologic oncology >Clinical-Prostate cancer A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy

【24h】

Clinical-Prostate cancer A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy

机译：临床前列腺癌是一种新颖的吲哚图组合PiRADS v2和中性粒细胞到淋巴细胞比率，以预测在第一次活检的PSA <10ng / ml的男性中临床上大型前列腺癌的风险

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective: To determine whether Prostate Imaging-Reporting and Data System version 2 (PIRADS v2) and neutrophil-to-lymphocyte ratio(NLR) improve the detection of clinically significant prostate cancer(csCaP) in men with prostate-specific antigen (PSA) <10 ng/ml at first biopsy.

机译：目的：确定前列腺成像报告和数据系统版本2（PiRADS V2）和中性粒细胞到淋巴细胞比（NLR）是否改善了具有前列腺特异性抗原（PSA）的男性的临床上重要前列腺癌（CScap）的检测< 第一次活检10ng / ml。

著录项

来源
《Urologic oncology》 |2020年第5期|共9页
作者
Sun JiaLe; Zhang ZhiYu; OuYang Jun;
展开▼
作者单位

Soochow Univ Affiliated Hosp 1 Dept Urol Suzhou Jiangsu Peoples R China;

Soochow Univ Affiliated Hosp 1 Dept Urol Suzhou Jiangsu Peoples R China;

Soochow Univ Affiliated Hosp 1 Dept Urol Suzhou Jiangsu Peoples R China;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词
PIRADS v2; Neutrophil-to-lymphocyte ratio; Prostate cancer; Clinically significant prostate cancer; Prostate biopsy; Nomogram;

机译：pirads v2;中性粒细胞到淋巴细胞比例;前列腺癌;临床显着的前列腺癌;前列腺活组织检查;罗维图;

相似文献

外文文献
中文文献
专利

1. 在初始PSA和Gleason评分较高的前列腺癌病人中前列腺活检术后分期MRI对T3疾病的预测力会降低 [J] . Young Hwii Ko, Deuk Jae Sung, Sung Gu Kang, 亚洲男性学杂志：英文版 . 2011,第003期
2. Clinical-Prostate cancer A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy [J] . Sun JiaLe, Zhang ZhiYu, OuYang Jun Urologic oncology . 2020,第5期

机译：临床前列腺癌是一种新颖的吲哚图组合PiRADS v2和中性粒细胞到淋巴细胞比率，以预测在第一次活检的PSA <10ng / ml的男性中临床上大型前列腺癌的风险
3. Is prostate volume better than PSA density and free/total PSA ratio in predicting prostate cancer in patients with PSA 2.5-10 ng/mL and 10.1-30 ng/mL? [J] . Erdogan Abdullah, Polat Salih, Keskin Ercument, The aging male: the official journal of the International Society for the Study of the Aging Male . 2020,第1期

机译：前列腺体积比PSA密度和自由/总PSA比率更好，以预测PSA 2.5-10ng / ml和10.1-30ng / ml患者的前列腺癌？
4. Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4–10 ng ml?1) [J] . Jun Liu, Zhi-Qian Wang, Min Li, Asian journal of andrology . 2020,第2期

机译：建立两种新的前列腺癌预测模型，以确定当PSA水平在诊断灰色区域时是否需要前列腺活检（4-10 ng×1）
5. Combining nomogram and microarray data for predicting prostate cancer recurrence [C] . Sun Yijun, Cai Yunpeng, Goodison Steve IEEE International Conference on BioInformatics and BioEngineering . 2008

机译：结合NOM图和微阵列数据来预测前列腺癌复发
6. Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy [D] . TAKEI, Akinori 2019

机译：雄激素剥夺治疗的持续时间和最低20 ng / dL的睾丸激素最低值可预测接受外照射的前列腺癌患者的睾丸激素恢复至超水平
7. Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4–10 ng ml−1) [O] . Jun Liu, Zhi-Qian Wang, Min Li, 2020

机译：建立两个新的前列腺癌预测模型以确定当PSA水平处于诊断性灰色区（4–10 ng ml-1）中时是否需要进行前列腺穿刺活检
8. MP14-11 PREDICTIVE VALUE OF PIRADS V2 FOR ANY AND CLINICALLY SIGNIFICANT PROSTATE CANCER ON PROSTATE BIOPSY IN A HIGH RISK ETHNIC COHORT [O] . Wilson Lin, Ethan Fram, Victoria Chernyak, 2018

机译：在高风险族群中对前列腺活组织检查的任何和临床显着的前列腺癌的Pirads V2的预测值

Clinical-Prostate cancer A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy

摘要

著录项

相似文献

相关主题

期刊订阅